Abstract
With the success of human genome projects, the focus of life science research has shifted to the functional and structural analyses of proteins, such as proteomics and structural genomics. These analyses of proteins including newly identified proteins are expected to contribute to the identification of therapeutically applicable proteins for various diseases. Thus, pharmaco-proteomic based drug discovery and development for protein therapies is most noticed currently. However, there is a clinical difficulty to use almost bioactive proteins, because of their very low stability and pleiotropic actions in vivo. To promote pharmaco-proteornic based drug discovery and development, we have attempted to establish a system for creating functional mutant proteins (muteins) with desired properties, and to develop a site-specific bioconjugation system for further improving their therapeutic potency. In this review, we are introducing these protein-drug innovation systems.
